- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Dey, L.P. v. Sunovion Pharma., Inc.
Clinical trial was not "public use" under 102(b), therefore summary judgment of invalidity was reversed.
July 15, 2013
Case Name: Dey, L.P. v. Sunovion Pharma., Inc., Case No. 2012-1428, 2013 U.S. App. LEXIS 10010 (Fed. Cir. May 20, 2013) (Circuit Judges Newman, Bryson, and O’Malley presiding; Opinion by Bryson; Dissent by Newman) (Appeal from S.D.N.Y., Koeltl, J.)
Drug Product and Patent(s)-in-Suit:Brovana® (formoterol); U.S. Patent Nos. 7,348,362, 7,462,645, 7,465,756, 7,473,710, and 7,541,385
Nature of the Case and Issue(s) Presented: The issue before the Federal Circuit was whether third-party clinical trials could constitute public use under 35 U.S.C. §102(b). Sunovion argued that its clinical trials, which were done under confidentiality agreements, constituted public use of the claimed invention in Dey’s asserted patents. The district court granted summary judgment of invalidity based on public use because Sunovion’s clinical trials were open and free, which is to say, the participants could take the drugs home and there were no repercussions for failing to return them. The district court also found that the confidentiality requirements were so “loose” that they did not preclude a finding of public use. In particular, the district court relied on the fact that (i) the participant was given the identity of the active ingredient in the study; and (ii) the participant was permitted to discuss the trial, including the drug that was the subject of that trial, with his/her regular doctor.
The Federal Circuit reversed the district court’s summary judgment ruling. It held that there existed genuine issues of fact, which precluded entry of summary judgment of invalidity.
Why Dey Prevailed: The Federal Circuit disagreed that the clinical trial participants had unfettered use of the trial drug. In particular, the Federal Circuit focused on the facts that the subjects agreed to take the medication, keep usage logs, and return any unused drugs at the end of the trial. Likewise, the test administrators could only dispense the drugs to trial participants, were held accountable for storage of the drugs, and knew that all unused drugs were to be returned. Therefore, the Federal Circuit held that there were genuine issues of fact that precluded summary judgment.
The Federal Circuit also disagreed with the district court’s finding concerning the lack of confidentiality associated with the clinical trial. The subjects were given incomplete descriptions of the treatment formulation; while they were informed about the active chemical compound and the range of possible dosages being investigated, they were not told the identity of the particular drug or formulation they were receiving. Thus, the subjects could not tell the inventive formulation to someone else. Further, that the participants did not sign confidentiality agreements did not render the trial a public use because participants routinely do not sign confidentiality agreements. Rather, the investigators were the most knowledgeable persons involved in the study, and they were required to sign a pledge of confidentiality. Thus, as to this issue too, Dey raised genuine issues of fact that precluded entry of summary judgment.
In her dissent, Judge Newman agreed with the majority’s opinion to reverse the district court, but disagreed with the decision to remand. “There are no disputed facts, and no facts requiring finding or that could be found to show that these trials were a public use. The issue requires resolution, not perpetuation.”
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.